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The utility of the GeneXpert MTB/RIF (Xpert) assay for detection ofMycobacterium tuberculosis in sputum samples has been
extensively studied. However, the performance of the Xpert assay as applied to other readily accessible body fluids such as ex-
haled breath condensate (EBC), saliva, urine, and blood has not been established. We used the Xpert assay to test EBC, saliva,
urine, and blood samples fromHIV-negative, smear- and culture-positive pulmonary tuberculosis (TB) patients for the presence
ofM. tuberculosis. To compare the ability of the assay to perform bacterial load measurements on sputum samples with versus
without sample processing, the assay was also performed on paired direct and processed sputum samples from each patient. The
Xpert assay detectedM. tuberculosis in none of the 26 EBC samples (sensitivity, 0.0%; 95% confidence interval [95% CI], 0.0%,
12.9%), 10 of the 26 saliva samples (sensitivity, 38.5%; 95% CI, 22.4%, 57.5%), 1 of 26 urine samples (sensitivity, 3.8%; 95% CI,
0.7%, 18.9%), and 2 of 24 blood samples (sensitivity, 8.3%; 95% CI, 2.3%, 25.8%). For bacterial load measurements in the differ-
ent types of sputum samples, the cycle thresholds of the twoM. tuberculosis-positive sputum types were well correlated (Spear-
man correlation of 0.834). This study demonstrates that the Xpert assay should not be routinely used to detectM. tuberculosis in
EBC, saliva, urine, or blood samples fromHIV-negative patients suspected of having pulmonary tuberculosis. As a test of bacte-
rial load, the assay produced similar results when used to test direct versus processed sputum samples. Sputum remains the opti-
mal sample type for diagnosing pulmonary tuberculosis in HIV-negative patients with the Xpert assay.
The ability to rapidly and accurately diagnose pulmonary tuber-culosis (TB) is an important component of effective disease
management. TB testing is most commonly performed on expec-
torated sputum. However, high-quality sputum samples can be
difficult to obtain from many patients, especially children and
persons with human immunodeficiency virus (HIV) infection.
The high viscosity of many sputum samples can also complicate
sample processing for nucleic acid amplification tests (NAAT).
The availability of more-accessible and mechanically tractable
sample types might be useful adjuncts for TB detection (1).
Exhaled breath condensate (EBC) has several properties that
make it a potentially attractive diagnostic matrix. Derived from
the respiratory fluid which lines pulmonary airways, EBC can be
easily and noninvasively obtained using relatively inexpensive col-
lection devices. EBC is already used to diagnose some lung diseases
(2–4). Saliva is another promising diagnostic matrix. It can be
easily collected with minimal discomfort, and it has been used to
screen large populations for some diseases (5–9). Blood and urine
samples are also relatively simple to collect from patients. A num-
ber of reports have detected DNA fromMycobacterium tuberculo-
sis in blood and urine samples from HIV-positive and -negative
patients with pulmonary TB (10–16); however, results of individ-
ual studies have been quite variable (10–12, 14, 15).
The GeneXpert MTB/RIF (Xpert) assay (Cepheid, Sunnyvale,
CA, USA) is the first rapid, near-patient, completely automated,
assay endorsed by theWorld Health Organization (WHO) for the
initial diagnosis of pulmonary TB (17–20). Given the high accu-
racy of this test in sputum samples (sensitivity and specificity of
90% and 99%, respectively), it represents a considerable advance
over smear microscopy (19, 21–23). The assay can be performed
either directly on unprocessed (raw) sputum samples or on pro-
cessed sputum pellets that have already been decontaminated and
liquefiedwithN-acetyl-L-cysteine and sodiumhydroxide (NALC-
NaOH), as a prelude toM. tuberculosis culture. It has been shown
that the Xpert assay is equally sensitive when performed with ei-
ther type of sputum sample (19). However, the assay also provides
quantitative information in the form of a cycle threshold (CT) that
has the potential to be used to monitor bacterial load (24). The
quantitative information provided by these two types of sputum
samples have never been rigorously compared.
Here, we undertook a study to determine whether body fluids
Received 3 July 2013 Returned for modification 26 August 2013
Accepted 2 October 2013
Published ahead of print 9 October 2013
Address correspondence to David Alland, allandda@njms.rutgers.edu.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.01743-13
December 2013 Volume 51 Number 12 Journal of Clinical Microbiology p. 4161–4166 jcm.asm.org 4161
 o
n
 M
arch 15, 2017 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
such as EBC, saliva, urine, or blood can be used instead of sputum
to diagnose TB using the Xpert assay. We also compared the bac-
terial load estimates generated by tests of unprocessed versus pro-
cessed sputum pellets.
MATERIALS AND METHODS
Study population. We analyzed clinical specimens from HIV-negative,
acid-fast bacilli (AFB) smear-positive andM. tuberculosis culture-positive
adult pulmonary TB patients whowere enrolled in another ongoing study
of TB biomarkers. Enrollment took place at two clinical sites, Stellenbosch
University, Cape Town, South Africa, and the National Medical Center
(NMC), Seoul, South Korea.
Ethics statement. This study was approved by the institutional review
boards (IRBs) of StellenboschUniversity andNMC, as well as the Univer-
sityMedicine andDentistry of New Jersey (UMDNJ) IRB (protocol num-
ber 0120100144, for use of nonhuman subjects research) and the NIAID
IRB (www.clinicaltrials.govNCT00341601). All subjects providedwritten
consent for the sample collection and study preparation.
Nonsputum specimen collection. EBC, saliva, urine, blood, and spu-
tum specimens were collected from each subject before initiation of anti-
tuberculosis treatment. Some patients were unable to provide one or
more of the sample types other than sputum samples. In this case, the
available samples were analyzed. Detailed procedures for collecting study
specimens are described below. EBC was collected using a commercially
available RTube device (Respiratory Research, Austin, TX,USA). Subjects
were asked to rinse their mouth with distilled water and then breathe at
normal tidal volumes into a mouthpiece attached to a cold condenser for
10 min. The mouthpiece was equipped with a saliva trap and a one-way
valve which permitted the condensate to accumulate within the cold con-
denser. Saliva was collected using a Salivette saliva collector (Sarstedt,
Nümbrecht, Germany). The Salivette saliva collector contained a cotton
swab that was placed in each subject’s mouth by a study nurse with twee-
zers. The participant was asked to chew the swab for 45 s to stimulate
salivation. The swabwas then collectedwith tweezers and placed back into
the empty Salivette tube.Within 2 h of collection, the tubewas centrifuged
for 2min at 1,000 g to collect approximately 1ml of saliva at the bottom
of the tube. Patients provided approximately 4.5 ml of a clean-catch mid-
stream urine sample in a sterile urine container supplemented with 0.5ml
of 10 urine stabilizer (0.6 M Tris [pH 7.4], 0.24 M EDTA). The final
5-ml sample was then transferred to a 15-ml tube and stored at 80°C.
Ten milliliters of blood was collected into EDTA-anticoagulated tubes by
venipuncture only for the South African cohort.
Sputum specimen collection. Each patient provided two different
deeply expectorated sputum samples (one early morning expectoration
representing overnight secretions collected at home and one spontane-
ously expectorated, i.e., spot sputum collected at the clinic). Early morn-
ing specimens were decontaminated by the standard NALC-NaOH
method (25), and the final sediment was resuspended in 1.0 ml of sterile
phosphate buffer (Na2HPO4, KH2PO4 [pH 6.8]). Part (0.5 ml) of this
pellet was used for mycobacterial growth indicator tube (MGIT) culture
at the clinic, and the other 0.5-ml aliquot of the processed sputum pellet
was stored at 80°C for testing by GeneXpert MTB/RIF (Xpert) assay
(Cepheid, Sunnyvale, CA). The 1-ml spot sputum samples were trans-
ferred to a 2-ml bar-coded plastic vial and stored at80°C for GeneXpert
analysis. To study quantitation in sputum, we continued periodic collec-
tion of morning and spot sputum samples on days 2, 7, 14, 28, 42, 56, 70,
84, and 168 even after starting antituberculosis therapy.
Storage and transport.All study sampleswere frozen at80°Cwithin
2 h of collection and transported ondry ice to the study analysis laboratory
at New Jersey Medical School, Rutgers Biomedical & Health Sciences
(RBHS), Newark, NJ, USA.
Sample processing for Xpert testing.All direct 1-ml sputum samples
were processed forGeneXpert per themanufacturer’s instructions (Ceph-
eid, Sunnyvale, CA, USA). For processed sputum pellets, 0.5 ml was
treatedwith 1ml sample reagent (SR),mixedwell, incubated for 15min at
room temperature (RT), and then the entire content of 1.5 ml was trans-
ferred to the Xpert cartridge. Saliva and EBC samples were processed as
described above for processed sputum pellets. However, whenever the
volume of the obtained sample was less than 0.5 ml, the volume was
increased to 0.5 ml with TET (50 mMTris [pH 8.35]. 0.1 mMEDTA, and
0.1%mMTween 20). The 5-ml urine samples were centrifuged at 3,500
g for 30min at 4°C. The supernatant was discarded, and the sediment was
resuspended in 700 l of sterile phosphate-buffered saline (pH 7.4)
(Sigma), and then 1.4 ml of SR was added to the resuspended pellet. The
tube containing the processed urine was capped and then manually agi-
tated twice during a 15-min incubation period at RT. Finally, 2 ml of the
sample was transferred to the Xpert cartridge. The 10-ml blood samples
were processed and concentrated into a 2-ml sample andusing a red blood
cell (RBC) lysis centrifugation protocol described elsewhere (26). The
entire 2 ml of processed blood was loaded into the Xpert cartridge.
Data analysis. All specimens showing an “invalid” or “error” or
“indeterminate” Xpert results were excluded from the final analysis. Xpert
assay sensitivity for each alternative biomaterial was calculated against
sputumMGIT cultures. MGIT cultures that were indicated as positive by
the MGIT 960 system were identified as contaminated if in-house PCR
(specific for M. tuberculosis) and/or the Capilia TB assay (TAUN,
Numazu, Japan) were negative. All contaminated MGIT cultures were
also excluded from the final data analysis.
Statistical analysis. Xpert assay sensitivity against MGIT culture re-
sults as the gold standardwas estimated using simple percentages and 95%
confidence intervals (95%CIs) calculated byWilson’s scoremethod.Wil-
coxon signed-rank test was used to compare the paired median cycle
threshold (CT) values after setting the CT value of the samples without
detectable M. tuberculosis to a value above the largest observed CT value.
McNemar’s test was used to compare sensitivity on sputum and other
biomaterials or on concentrated sputum. Repeated measures methods
with a simple compound symmetry correlation structure were used to
make comparisons that used data at multiple time points using the
GENMOD orMixed procedures to assess trends in genome detection, CT
values, and differences between direct and concentrated sputum. How-
ever, discordance of genome detection and Spearman correlation esti-
mates used to quantify the association between direct and concentrated
sputum CT values assumed independence. All testing and estimates were
calculated using SAS 9.2 (SAS Institute, Cary, NC, USA). Plots weremade
in Microsoft Excel 2007 and R 2.12.2 (The R Foundation for Statistical
Computing).
RESULTS
Patient enrollment and sample accrual. A total of 44 patients
with confirmed pulmonary TB were enrolled, 35 from South Af-
rica and 9 from South Korea (Table 1). Not every patient was able
TABLE 1 Xpert assay performance with different biomaterials from
culture-proven pulmonary TB cases
Sample type
(no. of
specimens)
No. of samples with the indicated result by the
following test:
Assay sensitivity
(%) (95% CI)a
MGIT culture
and
M. tuberculosis
detected
Xpert assay
M. tuberculosis
detected
M. tuberculosis
not detected
EBC (26) 26 0 26 0.0 (0.0, 12.9)
Saliva (26) 26 10 16 38.5 (22.4, 57.5)
Urine (26) 26 1 25 3.8 (0.7, 18.9)
Blood (24) 24 2 22 8.3 (2.3, 25.8)
Direct sputum
(31)
31 31 0 100.0 (87.9, 100.0)
Processed sputum
(pellet) (41)
41 41 0 100.0 (91.4, 100.0)
a Xpert assay sensitivity was calculated against sputum MGIT culture. The 95%
confidence intervals were calculated by using the Wilson score method.
Shenai et al.
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to provide every type of body fluid. Patients with compromised
respiratory status found it difficult to tolerate the EBC collection
device; other patients found saliva collection to be uncomfortable
orwere unable or unwilling to provide additional sputumor urine
samples. For the 35 South African patients, 17 EBC samples, 18
saliva samples, 18 urine samples, 24 blood samples, 25 direct (un-
processed) sputum samples, and 32 processed baseline sputum
samples were available for testing by the Xpert assay. For the nine
South Korean patients, 9 EBC specimens, 8 saliva specimens, 8
urine specimens, 6 direct sputum specimens, and 9 processed spu-
tum specimens were available for testing by the Xpert assay (Table
1). In addition to pretreatment samples, 209 direct sputum sam-
ples and 227 concentrated sputum samples were collected from
these 44 patients after initiating anti-TB treatment.
Invalid, error, and inhibition rates of the Xpert assay. We
examined Xpert assay invalid and error rates by sample type. In-
valid results and errors occurred in 4/268 (1.5%) of the processed
sputum samples and in 1/240 (0.4%) of the direct sputum sam-
ples. No invalid results or errors were observed in any of the EBC,
saliva, urine, or blood specimens. We also examined all of the
Xpert assays (whether positive or negative forM. tuberculosis) for
evidence of partial PCR inhibition. A sample was considered to
show evidence of partial PCR inhibition when the cycle threshold
(CT) of the Xpert assay’s internal control reactionwas greater than
34 (24). Assays with internal control CT values of 34 were ob-
served in 0 EBC samples, 1 (3.8%) saliva sample, 3 (12.5%) blood
samples, 5 (19.2%) urine samples, 8 direct (3.3%) sputum sam-
ples, and 11 (4.2%) concentrated sputum samples (P value of
inhibition in direct sputum samples versus EBC samples is 0.6,
versus saliva samples is 0.1, versus blood samples is 0.07, versus
urine samples is 0.001, and versus sputum pellets is 0.64).
Assay performance using nonsputum biomaterials. The
Xpert assay showed a low sensitivity for detecting M. tuberculosis
when it was applied to EBC, saliva, urine, and blood samples from
ourHIV-negative study patients (Table 1).M. tuberculosiswas not
detected in any of the 26 EBC samples (sensitivity, 0.0%; 95% CI,
0.0%, 12.9%). The Xpert assay was positive for M. tuberculosis in
only one of the 26 urine specimens (sensitivity, 3.8%; 95% CI,
0.7%, 18.9%) and 10/26 saliva specimens (sensitivity, 38.5%; 95%
CI, 22.4%, 57.5%). It was also positive for M. tuberculosis in 2/24
blood specimens (sensitivity, 8.3%; 95% CI, 2.3%, 25.8%). These
results compare poorly to the performance of the Xpert assay
when testing direct or processed sputum samples isolated from
the same patients (P 0.001) where sensitivity was 100%, consis-
tent with prior reports (19).
We next compared the CT values of samples of each body fluid
to the CT value of the direct sputum sample taken from the same
patient during the same initial study visit. Therewas no clear trend
between the number of M. tuberculosis genomes detected in the
sputum sample (as reflected by assay CT value) and either assay
positivity or the number of genomes detected in the other body
fluid (Fig. 1). Among the samples with positive assay results, the
CT values were high in saliva (medianCT value, 31.4; range, 27.6 to
34.3), urine (median, 32.2), and blood (median, 30; range, 28.0 to
31.9) compared to corresponding sputum samples (median CT
value, 20.3; range, 16.1 to 34.7), indicating a lower bacterial load in
the nonsputum specimens.
Comparison of bacterial load quantitation using direct ver-
sus processed sputum samples. In addition to the 31 pretreat-
ment paired direct and processed sputum samples provided by 31
TB patients, we obtained an additional 208 paired samples from
these same patients during the course of their TB treatment. The
inclusion of samples obtained during treatment allowed us to
compare the performance of the Xpert assay over a very wide
bacterial load. During treatment, the assay positivity rates de-
creased in both sample types compared to the 100%positivity seen
before treatment (both P 0.001). Among the 239 patient/sam-
pling times with both direct and processed sputum results, 199
were concordant positive and 23 concordant negative. Of the 17
samples with discordant results, 10 samples had a positive result
on a direct sputum sample and a negative result on a processed
sputum sample, and 7 samples had a positive result on a processed
sputum sample and a negative result on a direct sputum sample;
the positivity rates using the two sample types for patients be-
ing treated for TB were not statistically different (P  0.53 by
FIG 1 Detection of TB in different body fluids collected from culture-proven
pulmonary TB cases. The Xpert assay was used to test each body fluid, EBC,
saliva, urine, and blood, for TB. The assay cycle threshold (CT) (Ct in the
figure) values for each body fluid are compared to the CT value of the direct
sputum sample collected from the same patient on the same day. Samples
where TBwas not detected have been plotted at aCT value of 40, which is above
the highest CT value used to identify TB in the Xpert assay.
Alternate Biomaterials for Diagnosis of Pulmonary TB
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McNemar’s test). At each sampling time, we found no difference
in the distribution of CT values in direct or concentrated sputum
samples by Wilcoxon signed-rank test, and there was no statisti-
cally significant difference inCT values (Table 2), which were sim-
ilar over all time points. As shown in Fig. 2, the CT values for all
time points were strongly correlated (Spearman correlation of
0.834) and the difference in CT values using direct and processed
sputum samples were not statistically significant (P 0.39).
DISCUSSION
The ability of the Xpert assay to detect TB in sputum samples has
been studied extensively. However, sputum samples may be diffi-
cult to obtain from children and from the infirm. The quality of
sputum that individual patients produce may also be quite vari-
able. Cultural factors can also limit the ability to collect a good
sputum sample (27). These factors led us to investigate whether
body fluids that might be more accessible than sputum could be
used to detect TB using the Xpert assay. Our study is the first to
systematically examine the performance of the Xpert assay on
EBC and saliva samples and the first to examine the performance
of the Xpert assay on urine and blood samples fromHIV-negative
subjects.
EBChas the potential to be an ideal diagnosticmatrix. EBC can
be collected noninvasively, it is derived directly from the lungs,
and it has a viscosity similar to the viscosity of water (2). In gen-
eral, however, EBChas been a disappointing diagnostic sample for
respiratory pathogens. For example, several PCR studies showed
that tests of EBC were less sensitive for detecting respiratory vi-
ruses than tests of samples collected by standard techniques (28,
29). EBC was also shown to be an inferior diagnostic matrix for
detecting M. tuberculosis DNA from patients with active pulmo-
nary TB using in-house assays (4, 30). However, the Xpert assay
uses an internal filter to concentrate intact bacteria, permitting
almost 1 ml of EBC to be concentrated and tested for TB. The
Xpert assay is also highly sensitive and specific. These two features
raised the possibility that the Xpert assay would perform well on
tests of EBC samples. Unfortunately, we were unable to detectM.
tuberculosis DNA in any of the 26 EBC specimens tested. These
negative results occurred even though many of the patients were
shown to have very high pulmonary loads of TBon the sameday as
the EBC samples were obtained. Our study does lead to the inter-
esting conclusion that patients with pulmonary TB are very un-
likely to transmit their disease by breathing.
Saliva is another promising diagnostic matrix for the Xpert
assay. Eguchi et al. detected M. tuberculosis DNA in mixed saliva
samples from HIV-negative patients with pulmonary TB using a
nested PCR targeting IS6110 insertion element with 98% sensitiv-
ity (31). In contrast, our study of 26 culture-positive pulmonary
TABLE 2 Comparison of Xpert results (minimum rpoB CT values) between paired direct and processed sputum specimens for each time point from
culture-proven pulmonary TB cases
Time points
(no. of days)
No. of
specimens
Direct sputum Processed sputum (pellet)
P value for test
difference in
median CT
c
Median of each CT between
processed and direct sputum
specimen (range)
No. of
specimensa
Median CT
b
(range)
No. of
specimens
Median CT
(range)
0 31 31 (100) 19.3 (14.6–36.7) 31 (100) 20.1 (12.5–32.1) 0.51 0.5 (13.1 to 6.2)
2 34 33 (97) 21.4 (10.8–29.2) 33 (97) 20.2 (9.9–29.4) 1.00 0.35 (7.6 to 6.0)
7 27 25 (93) 21.8 (13.8–35.0) 25 (93) 19.7 (9.9–29.4) 0.50 0.00 (7.6 to 5.8)
14 30 29 (97) 21.9 (14.9–35.1) 29 (97) 22.1 (15.6–34.4) 0.34 0.95 (9.5 to 8.2)
28 26 21 (81) 23.4 (14.0–33.3) 22 (85) 26.5 (12.1–34.3) 0.54 0.5 (26.4 to 33.0)
42 21 18 (86) 25.3 (18.4–32.8) 19 (90) 26.4 (14.5–35.4) 0.92 0.6 (32.8 to 32.2)
56 19 16 (84) 27.6 (16.9–37.6) 14 (74) 28.2 (15.6–37.8) 0.60 0.00 (29.3 to 7.9)
70 15 12 (80) 25.7 (15.2–32.0) 11 (73) 28.2 (13.7–33.5) 0.35 0.00 (28.9 to 7.5)
84 20 17 (85) 26.8 (15.2–34.5) 17 (85) 29.8 (17.2–35.6) 0.19 1.95 (29.7 to 32.9)
168 16 7 (44) 25.2 (20.4–32.7) 5 (31) 25.9 (17.2–31.6) 0.16 0.00 (32.7 to 4.1)
a The values in parentheses are the percentage of specimens in which M. tuberculosis was detected.
b The cycle threshold in the specimens in which M. tuberculosis was detected.
c Results of a two-sided Wilcoxon signed-rank test performed after setting samples without M. tuberculosis detected to a value above the highest observed CT value for those
detected.
FIG 2 Correlation between direct and processed sputum specimens collected
from confirmed pulmonary TB cases at the baseline and during treatment. The
Xpert assay was performed on paired samples. The cycle threshold (CT) (Ct in
the figure) value for each direct sputum sample is plotted in comparison to the
CT value of the processed sputum sample obtained from the same patient on
the same day. Samples where TB was not detected have been plotted at a CT
value of 40, which is above the highest observed CT value.
Shenai et al.
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TB patients found only 10 subjects with M. tuberculosis-positive
saliva samples when tested with the Xpert assay. It is unclear why
the Xpert assay performed so poorly on saliva compared to the
study by Eguchi et al. (31). False-positive results generated by the
nested PCR assay used by Eguchi et al. could be one explanation.
Nested PCR is prone to false-positive results from amplicon cross
contamination. In contrast, the integrated cartridge-based Xpert
assay is designed to minimize sample cross contamination and
false-positive results. Indeed, the Xpert assay has been shown to be
very specific in clinical studies, using sputum as the test matrix
(19, 23, 32). It is worth noting that only 17.3% of the patients
studied by Eguchi et al. were culture positive for M. tuberculosis
(31), a culture-positive rate that was much lower than the PCR-
positive rate. Given the relatively poor sensitivity of the Xpert
assay in our saliva study, we suggest that saliva is unlikely to be a
clinically useful diagnostic matrix when sputum is available.
A number of previous studies have suggested that M. tubercu-
losis DNA can be detected in urine samples from patients with
pulmonary TB, although the sensitivity, specificity, and tech-
niques used varied between studies (13, 14, 33–35). The Xpert
assay has also been shown to have relatively good sensitivity for
detecting M. tuberculosis in urine samples from TB patients with
unknownHIV status (36) and from patients who are known to be
HIV positive (14, 36, 37). Our study was the first, to our knowl-
edge, to examine the ability of the Xpert assay to detect M. tuber-
culosis in the urine samples of patients known to be HIV negative.
We detectedM. tuberculosis in only 1 of the total 26 urine samples
tested. The renal and urinary system history of this patient re-
vealed diabetes mellitus nephropathy with renal stones, but there
was no evidence of renal TB. The poor performance of our study
compared to previous ones could be due to the fact that the Xpert
assay detects intact, filterable bacteria rather than free DNA. In
contrast, some other positive studies extracted M. tuberculosis
DNA directly from the urine sample (13, 34). The use of a urine
stabilizer that contained 0.24 M EDTA and a protocol that in-
cluded concentration by centrifugation might also have contrib-
uted to poor assay sensitivity by causing some PCR inhibition.
Indeed, at least some PCR inhibition was detected in approxi-
mately one-fifth (5/26) of our urine samples, as indicated by a CT
value of 34 cycles in the internal PCR control included in the
Xpert assay. However, it should be noted that the self-contained
cartridge used by the Xpert assay permits TB to be tested with very
high specificity, since sample cross contamination is easily
avoided. Thus, it is possible that our results correctly indicate that
M. tuberculosis is rarely present in urine samples from HIV-nega-
tive TB patients and that free circulating DNA or false-positive
results may have contributed to the high detection rates in previ-
ous studies.
M. tuberculosis has been detected in blood samples from TB
patients with variable degrees of sensitivity (10–12, 15, 16, 38, 39).
Most TB patients with positive blood tests have beenHIV positive
(12), and the highest sensitivities reported for HIV-negative pa-
tients were 43.8% and 40% (11). However, many of these prior
studieswere poorly controlled, and the specificity of the assay used
was often uncertain. A recent study showed that the Xpert assay
detected TB in blood samples from HIV-positive patients with a
sensitivity approximately equal to the sensitivity of blood culture
(40). However, we found that only 8.3% of the HIV-negative sub-
jects in our study were TB positive upon blood testing. Thus,
blood testing with the Xpert assay should probably be reserved for
TB suspects who are HIV positive.
We found that the Xpert assay detectedM. tuberculosis in both
direct sputum samples and processed sputum pellets of TB pa-
tients with high sensitivity. The sensitivity of the two types of
sputum samples was not statistically different, although a few
more sampleswere positive in tests of direct sputum samples com-
pared to tests of processed sputum samples. These results are in
accord with previous studies (19). New to our study was the find-
ing that both sputum sample types detected remarkably similar
quantities ofM. tuberculosisDNA, as estimated byCT value, when
obtained from the same patient on the same day. This suggests
that these sputum types can be used interchangeably for quanti-
tation studies.
Our investigation has a few limitations. Except for the sputum
studies, we tested a relatively small number of each type of sample
matrix. However, it is unlikely that a much larger study would
have found that any of these types of samples has a sensitivity
acceptable for clinical use. The “gold standard” M. tuberculosis
cultures were performed on fresh sputum samples, while all the
Xpert tests were performed on frozen samples. However, prior
studies have suggested that freezing does not affect the perfor-
mance of the Xpert assay on direct or processed sputum (41, 42),
urine, or other extrapulmonary specimens (35).Our study did not
include samples from negative-control patients without TB; thus,
it was not designed to examine assay specificity. Specificity testing
would have been needed if we had determined that the Xpert assay
could be usefully performed on EBC, saliva, urine, or blood sam-
ples. However, the low sensitivity which we discovered renders
this point moot.
To summarize, we found that TB cannot be routinely detected
from EBC, saliva, urine, or blood samples fromHIV-negative pa-
tients with pulmonary TB. On the other hand, the Xpert assay has
equal sensitivity in tests of both direct and concentrated sputum
samples. M. tuberculosis genomes are also equally quantitated in
both sputum types. Fresh or frozen sputum (direct or processed)
appears to be the best specimen by far to diagnose pulmonary TB
using the Xpert assay. Efforts to further improve the sensitivity of
the Xpert assay should focus on developing methods to obtain
better andmore consistent sputum samples that contain minimal
amounts of saliva. Approaches that permit larger volumes of spu-
tum to be tested in the Xpert assay may also improve detection.
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